Literature DB >> 11536136

Economic comparison between conventional and disposables-based technology for the production of biopharmaceuticals.

J L Novais1, N J Titchener-Hooker, M Hoare.   

Abstract

Time to market, cost effectiveness, and flexibility are key issues in today's biopharmaceutical market. Bioprocessing plants based on fully disposable, presterilized, and prevalidated components appear as an attractive alternative to conventional stainless steel plants, potentially allowing for shorter implementation times, smaller initial investments, and increased flexibility. To evaluate the economic case of such an alternative it was necessary to develop an appropriate costing model which allows an economic comparison between conventional and disposables-based engineering to be made. The production of an antibody fragment from an E. coli fermentation was used to provide a case study for both routes. The conventional bioprocessing option was costed through available models, which were then modified to account for the intrinsic differences observed in a disposables-based option. The outcome of the analysis indicates that the capital investment required for a disposables-based option is substantially reduced at less than 60% of that for a conventional option. The disposables-based running costs were evaluated as being 70% higher than those of the conventional equivalent. Despite this higher value, the net present value (NPV) of the disposables-based plant is positive and within 25% of that for the conventional plant. Sensitivity analysis performed on key variables indicated the robustness of the economic analysis presented. In particular a 9-month reduction in time to market arising from the adoption of a disposables-based approach, results in a NPV which is identical to that of the conventional option. Finally, the effect of any possible loss in yield resulting from the use of disposables was also examined. This had only a limited impact on the NPV: for example, a 50% lower yield in the disposable chromatography step results in a 10% reduction of the disposable NPV. The results provide the necessary framework for the economic comparison of disposables and conventional bioprocessing technologies. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536136     DOI: 10.1002/bit.1182

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  3 in total

1.  Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: A Review.

Authors:  Ou Yang; Maen Qadan; Marianthi Ierapetritou
Journal:  J Pharm Innov       Date:  2019-01-25       Impact factor: 2.750

2.  Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.

Authors:  Andreas Hougaard Laustsen; Netty Dorrestijn
Journal:  Toxins (Basel)       Date:  2018-07-31       Impact factor: 4.546

3.  Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.

Authors:  Suzanne S Farid; Max Baron; Christos Stamatis; Wenhao Nie; Jon Coffman
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.